Publications by authors named "Eva Lin"

Claim this Profile
K
KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077).
Kyung W Song, Christy C Ong, Eva Lin, Jeff Lau, Nicole M Sodir

Mol Cancer Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3Kα inhibitor and degrader inavolisib can co-opt FGFR2 to enhance responses in patients with PIK3CA-mutated solid tumors and in preclinical models.
Dejan Juric, Kyung Song, Radia M Johnson, Melissa K Accordino, Philippe L Bedard, Kevin Kalinsky, Eva Lin, Yanling Jin

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy.
Ashley V DiMarco, Mirunalini Ravichandran, Jeff Lau, Anthony Lima, Jennifer Lacap, Eva Lin

Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis.
Ryan J Conrad, James A Mondo, Mike Lingjue Wang, Peter S Liu, Zijuan Lai, Qingling Li, Eva Lin

EMBO Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COP1 Deficiency in BRAF Melanomas Confers Resistance to Inhibitors of the MAPK Pathway.
Ada Ndoja, Christopher M Rose, Eva Lin, Rohit Reja, Jelena Petrovic

Cells· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aryl Acid-Alcohol Cross-Coupling: C(sp)-C(sp) Bond Formation from Nontraditional Precursors.
Eva Lin, Johnny Z Wang, Edna Mao, Stephanie Tsang, Kurtis M Carsch

J Am Chem Soc· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.
Xueping Qu, Habib Hamidi, Radia M Johnson, Ethan S Sokol, Eva Lin

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma.
Andrew Goetz, Frances Shanahan, Logan Brooks, Eva Lin, Rana Mroue

bioRxiv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma.
Andrew Goetz, Frances Shanahan, Logan Brooks, Eva Lin, Rana Mroue

Cancers (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity.
Junghyun Lim, Ryan Rodriguez, Katherine Williams, John Silva, Alan G Gutierrez, Eva Lin

Cancer Immunol Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-coupling by a noncanonical mechanism involving the addition of aryl halide to Cu(II).
Connor P Delaney, Eva Lin, Qinan Huang, Isaac F Yu, Guodong Rao

Science· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Thijs J Hagenbeek, Jason R Zbieg, Marc Hafner, Rana Mroue, Jennifer A Lacap, Eva Lin

Nat Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, Eva Lin

Am J Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, Tom Januario, Brian D Hamman, Eva Lin, Michael Berlin

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of statistical approaches for association testing in noisy drug screening data.
Petr Smirnov, Ian Smith, Zhaleh Safikhani, Wail Ba-Alawi, Farnoosh Khodakarami, Eva Lin

BMC Bioinformatics· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors.
Kristin M Zimmerman Savill, Brian B Lee, Jason Oeh, Jie Lin, Eva Lin, Kui Lin

Nat Commun· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis.
Nikta Feizi, Sisira Kadambat Nair, Petr Smirnov, Gangesh Beri, Christopher Eeles, Eva Lin

Nucleic Acids Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orchestrating and sharing large multimodal data for transparent and reproducible research.
Anthony Mammoliti, Petr Smirnov, Minoru Nakano, Zhaleh Safikhani, Christopher Eeles, Eva Lin

Nat Commun· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines.
Line Mygland, Shoshy Alam Brinch, Martin Frank Strand, Petter Angell Olsen, Aleksandra Aizenshtadt, Eva Lin

iScience· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Ivana Yen, Frances Shanahan, Jeeyun Lee, Yong Sang Hong, Sang Joon Shin, Eva Lin

Nature· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways.
Trang H Pham, Thijs J Hagenbeek, Ho-June Lee, Jason Li, Christopher M Rose, Eva Lin

Cancer Discov· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Anneleen Daemen, Jonathan E Cooper, Szymon Myrta, Matthew J Wongchenko, Eva Lin

Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards in vitro in vivo correlation for modified release subcutaneously administered insulins.
Frederik Bock, Eva Lin, Claus Larsen, Henrik Jensen, Kasper Huus

Eur J Pharm Sci· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.
Victoria E Wang, Jenny Y Xue, Dennie T Frederick, Yi Cao, Eva Lin

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.
Ivana Yen, Frances Shanahan, Mark Merchant, Christine Orr, Thomas Hunsaker, Xiaolin Zhang, Eva Lin

Cancer Cell· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis